Page 149 - 2019年11月第30卷第21期

dynamic evidence of a competitive effect[J]. Thromb Res， tion study of ticagrelor and cyclosporine in healthy volun-
2008，121（4）：527-534. teers[J]. Clin Drug Investig，2014，34（8）：529-536.
[42] HOCHHOLZER W，KLEINER P，YOUNAS I，et al. Ran- [53] SINGH S，MALM CJ，RAMSTROM S，et al. Adrenaline
domized comparison of oral P2Y12-receptor inhibitor enhances in vitro platelet activation and aggregation in
loading strategies for transitioning from cangrelor：the ex- blood samples from ticagrelor-treated patients[J]. Res
celsiorLOAD2 trial[J]. JACC Cardiovasc Interv，2017，10 Pract Thromb Haemost，2018，2（4）：718-725.
（2）：121-129. [54] SINGH S，DAMEN T，NYGREN A，et al. Adrenaline im-
[43] FARID NA，KURIHARA A，WRIGHTON SA. Metabo- proves platelet reactivity in ticagrelor-treated healthy vol-
lism and disposition of the thienopyridine antiplatelet unteers[J]. Thromb Haemost，2019，119（5）：735-743.
drugs ticlopidine，clopidogrel，and prasugrel in humans[J]. [55] WIVIOTT SD，BRAUNWALD E，ANGIOLILLO DJ，
J Clin Pharmacol，2010，50（2）：126-142. et al. Greater clinical benefit of more intensive oral anti-
[44] KUBICA J，ADAMSKI P，OSTROWSKA M，et al. Mor- platelet therapy with prasugrel in patients with diabetes
phine delays and attenuates ticagrelor exposure and action mellitus in the trial to assess improvement in therapeutic
in patients with myocardial infarction：the randomized， outcomes by optimizing platelet inhibition with prasug-
double-blind，placebo-controlled IMPRESSION trial[J]. rel-thrombolysis in myocardial infraction 38[J]. Circula-
Eur Heart J，2016，37（3）：245-252. tion，2008，118（25）：1626-1636.
[45] IBRAHIM K，SHAH R，GOLI RR，et al. Fentanyl delays [56] NARDIN M，VERDOIA M，SARTORI C，et al. Diabetes
the platelet inhibition effects of oral ticagrelor：full report mellitus，glucose control parameters and platelet reactivity
of the PACIFY randomized clinical trial[J]. Thromb Hae- in ticagrelor treated patients[J]. Thromb Res，2016.DOI：
most，2018，118（8）：1409-1418. 10.1016/j.thromres.2016.04.021.
[46] HOBL EL，REITER B，SCHOERGENHOFER C，et al. [57] VERDOIA M，PERGOLINI P，NARDIN M，et al. Preva-
Morphine interaction with prasugrel：a double-blind， lence and predictors of high-on treatment platelet reactivi-
cross-over trial in healthy volunteers[J]. Clin Res Cardiol， ty during prasugrel treatment in patients with acute coro-
2016，105（4）：349-355. nary syndrome undergoing stent implantation[J]. J Cardi-
[47] ANDERSON JL，ADAMS CD，ANTMAN EM，et al. ol，2019，73（3）：198-203.
2012 ACCF/AHA focused update incorporated into the [58] EDWARD G，YAN L，HOLLIS BW，et al. 25-hydroxyvita-
ACCF/AHA 2007 guidelines for the management of pa- min D and risk of myocardial infarction in men：a prospec-
tients with unstable angina/non-ST-elevation myocardial tive study[J]. Archives of Internal Medicine，2008，168
infarction：a report of the American college of cardiology （11）：1174-1180.
foundation/American heart association task force on prac- [59] SILVAGNO F，VIVO ED，ATTANASIO A，et al. Mito-
tice guidelines[J]. Circulation，2013，127（23）：e663-828. chondrial localization of vitamin D receptor in human
[48] O’GARA PT，KUSHNER FG，ASCHEIM DD，et al. platelets and differentiated megakaryocytes[J]. PLoS One，
2013 ACCF/AHA guideline for the management of ST-ele- 2010，5（1）：e8670.
vation myocardial infarction：a report of the American col- [60] VERDOIA M，PERGOLINI P，ROLLA R，et al. Vitamin
lege of cardiology foundation/American heart association D levels and high-residual platelet reactivity in patients re-
task force on practice guidelines[J]. Circulation，2013，127 ceiving dual antiplatelet therapy with clopidogrel or ti-
（4）：e362-425. cagrelor[J]. Platelets，2016，27（6）：576-582.
[49] 赵雪银，王晓，聂绍平. P2Y12受体抑制剂与他汀类药物 [61] ASHER E，FRYDMAN S，KATZ M，et al. Chewing ver-
相互作用的研究进展[J].中国心血管病研究，2016，14 sus swallowing ticagrelor to accelerate platelet inhibition
（9）：776-779. in acute coronary syndrome-the CHEERS study. for the
[50] FARID NA，SMALL DS，PAYNE CD，et al. Effect of ator- PLATIS（platelets and thrombosis in sheba）study group
vastatin on the pharmacokinetics and pharmacodynamics [J]. Thromb Haemost，2017，117（4）：727-733.
of prasugrel and clopidogrel in healthy subjects[J]. Phar- [62] DEHARO P，QUILICI J，BONNET G，et al. Is platelet in-
macotherapy，2008，28（12）：1483-1494. hibition correlated with time from last intake on P2Y12
[51] ZHANG C，SHEN L，CUI M，et al. Ticagrelor-induced blockers after an acute coronary syndrome? a pilot study
life-threatening bleeding via the cyclosporine-mediated [J]. Platelets，2016，27（8）：791-795.
drug interaction：a case report[J]. Medicine（Baltimore）， （收稿日期：2019-06-09 修回日期：2019-07-30）
2017，96（37）：e8065. （编辑：唐晓莲）
[52] TENG R，KUJACIC M，HSIA J. Pharmacokinetic interac-

·3024 · China Pharmacy 2019 Vol. 30 No. 21 中国药房 2019年第30卷第21期